Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial

BACKGROUND: Dolutegravir concentrations are reduced by efavirenz induction effect necessitating twice-daily dolutegravir dosing when coadministered. Efavirenz induction persists for several weeks after stopping, which could potentially select for dolutegravir resistance if switching occurred with un...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Ying, Griesel, Rulan, Omar, Zaayid, Simmons, Bryony, Hill, Andrew, van Zyl, Gert, Keene, Claire, Maartens, Gary, Meintjes, Graeme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209436/
https://www.ncbi.nlm.nih.gov/pubmed/36645792
http://dx.doi.org/10.1093/cid/ciad023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10209436/
https://www.ncbi.nlm.nih.gov/pubmed/36645792
http://dx.doi.org/10.1093/cid/ciad023

Ejemplares similares